Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Kara Alaimo is an associate professor of communication at Fairleigh Dickinson University. Her book “Over the Influence: Why Social Media Is Toxic for Women and Girls — And How We Can Take It Back” was ...

phpstan 2.1.18 crashes with an out-of-memory or with --xdebug (and a sufficiently high memory limit) this error: Internal error: Maximum call stack size of 8339456 bytes (zend.max_allowed_stack_size - ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

So, you want to get good at LeetCode, especially using Java? It’s a common goal for a lot of us trying to land those tech jobs. This guide is all about helping you get there. We’ll go over how to ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Either way, let’s not be in denial about it. Credit...Illustration by Christoph Niemann Supported by By Kevin Roose and Casey Newton Kevin Roose and Casey Newton are the hosts of The Times’s “Hard ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...